RxDoctor Payments Data

Ignacio Gallardo, MD

Cardiovascular Disease · Pisgah Forest, NCNPI 1407896913

Payments from drug & device makers

$1,985in general payments, 2019–2025

Across 116 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$403
  • Biotronik Inc.$263
  • Astellas Pharma US Inc$245
  • Abbott$209
  • Medtronic$187
  • Novartis$184
  • plus $494 from 14 others

What the payments were for

  • Food & beverage$1,66284%
  • Education$32216%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,985 in reported general payments places this provider in the 45th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$34,100
Medicare patients
232
Services billed
427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$28,386
FarxigaDapagliflozin Propanediol24$14,638
EntrestoSacubitril/Valsartan11$8,625
Ranolazine ErRanolazine15$913
Isosorbide Dinitrate15$526
Flecainide Acetate22$478
Metoprolol Succinate54$451
ClopidogrelClopidogrel Bisulfate73$401
Amlodipine Besylate31$143
Losartan Potassium24$130
Amiodarone Hcl15$126
Isosorbide Mononitrate ErIsosorbide Mononitrate27$121
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$119
Spironolactone25$103
Carvedilol15$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$75$28,38634 claims
AstraZenecaFarxiga$47$14,63824 claims
NovartisEntresto$184$8,62511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Pisgah Forest

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →